Compound as cholinesterase inhibitor and its isolation from...

Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acids and salts thereof

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C562S474000, C514S568000

Reexamination Certificate

active

06759552

ABSTRACT:

FIELD OF INVENTION
The present invention relates to a compound 12-(12′-CARBOXY-5′-METHOXYPHENYL)-2,12′-DIHYDROXY-DODECA-4-ONE “Sporotricolone”, mainly as acetylcholinesterase (AchE) inhibitor. The present invention also relates to a process for the isolation of said compound from fungus Sporotrichum species.
BACKGROUND AND PRIOR ART REFERENCES
Enzyme inhibitors are important class of molecules that are used as drugs and pesticides. The enzyme acetylcholinesterase (AchE) is involved in the synaptic transmission of the nerve impulse and its inhibition leads to accumulation of the neurotransmitter, acetylcholine leading to overexcitation of the postsynaptic neuron. This property of the inhibitor has been exploited to develop newer insecticides against a wide range of insect pests as well as drugs effective against worms, and, recently a new class of neuroactive drugs against dementia (Alzheimer's).
Although earlier authors have isolated metabolites such asasteric acis, questin and questinol from Sorotricum sp., no AchE inhibitor activity has been reported (Slater, G P, Haskins, R H and Hogge, L. R. Can J Microbiol 17 (1971), 1576-79). The fungi,
Aspergillus terreus
(Ling, K H, Liou, H H, Yang, C M and Yang C K, Appl. Env. Microbiol, 37 (1979) 355-57) and Penicillium sp. (Omura, Skuno, F, Otoguro, K, Shiomi, K. Mauma, R and Iwai, Y. J. Antibiot. 48 (1995) 745-46) have been reported to produce an AchE inhibitor named Arusigacin. However, the AchE inhibitor of the present invention is isolated from Sporotrichum having distinct chemical structure and properties and therefore a novel inhibitor molecule.
After screening of various microorganisms, a fungal culture is selected which shows inhibition against a serine esterase/protease/cholinesterase enzyme. This imperfect deuteromycetes, Sporotrichum species and was first isolated in 1966. The taxonomic features of Sporotrichum species (deuteromyces) are broad hyphae and septae in nature; has hyalline conidiophores with little differentiation from vegetative hyphae and solitary conidia with broad attachment to the hyphae.
This culture has previously been a subject of research investigation at the Central Food Technological Research Institute (CFTRI) India, for its ability to grow on lignocellulosic wastes for the production of enzymes and organic acids (Sreekantaiah, K R, PhD thesis (1976) University of Mysore; Manonmani, H K, pHD thesis (1986) University of Mysore).
This culture has now been used in the present invention to produce a femented extract containing a serine esterase/protease/cholinesterase inhibitor.
The conditions of fermentation have been described earlier in Indian Patent Application No. 303/DEL/2000 Sattur, A P, Shivanandappa, T, Divakar, S and Karanth, N G.
OBJECTS OF THE INVENTION
The main object of the present invention is to provide bioactive compound 12-(2′-CARBOXY-5′-METHOXYPHENYL)-2,12-DIHYDROXY-DODECA-4-ONE “Sporotricolone” having inhibitory activity against acetylcholinesterase (AchE). Another object of the present invention is to provide a compound having inhibitory activity against serine esterase and protease.
Yet another object of the present invention is to provide a compound having insecticidal properties.
Still another object of the present invention is to provide a compound having enhanced cholinergic activity.
Yet another object of the present invention is to provide a process for the isolation of Sporotricolone.
SUMMARY OF THE INVENTION
The present invention provides a compound 12-(2′-CARBOXY-5′-METHOXYPHENYL)-2,12-DIHYDROXY-DODECA-4-ONE “Sporotricolone” mainly as acetylcholinesterase (AchE) inhibitor. The present invention also provides a process for the isolation of said compound from fungus Sporotrichum species.
DETAILED DESCRIPTION OF THE INVENTION
Accordingly, the present invention provides a bioactive compound 12-(2′-CARBOXY-5′-METHOXYPHENYL)-2,12-DIHYDROXY-DODECA-4-ONE “Sporotricolone” of formula (I) having acetylcholinesterease (AchE) enzyme inhibition activity obtained from fungus Sporotrichum species.
An embodiment of the present invention wherein the compound 12-(2′-CARBOXY-5′-METHOXYPHENYL)-2,12-DIHYDROXY-DODECA-4-ONE “Sporotricolone” of formula (I) having the following characteristic properties:
Solubility: Highly soluble in ethyl acetate, methanol and acetone. UV (ethylene acetate) &lgr;
max
: 265 nm, 312 nm.
1
HNMR spectrum (DMSO, &dgr;
TMS
=0.00 ppm); &dgr; 1.03 (3H, d, J=6.3 Hz, —CH—C
H
3
) &dgr; 1.2-2.7 (14H, m, 7x—C
H
2
) &dgr; 3.6-3.8 (m, Ar—O—C
H
3
and Ar—C
H
—OH) &dgr; 7.20 (1H, d, J=2.5 Hz, C
6′

H
) &dgr; 7.30 (2H, d, J=7.1 Hz, C
3′

H
and C
4′

H
)
Mass spectrum (EI, 70 eV, 25° C., 200-ul amp): m/e: 336 (M+), 279(366-87), 167(274-112), 57(CH
2
COCH
3
), 43, 29.
Another embodiment of the present invention, wherein the purity of the compound is established by TLC and RP HPLC.
Yet another embodiment of the present invention, wherein said compound is named as 12-(2′-CARBOXY-5′-METHOXYPHENYL)-2,12′-DIHYDROXY-DODECA-4-ONE “Sporotricolone”.
Still another embodiment of the present invention, wherein said compound is an inhibitor of the enzyme acetylcholinesterase from the rat brain as well as erythrocytes with a IC
50
value of 20×10
−6
M.
Yet another embodiment of the present invention, wherein said compound also acts as an inhibitor of serine esterase of the rat liver serum.
Still another embodiment of the present invention, wherein said compound having insecticidal properties.
Yet another embodiment of the present invention, wherein said compound effective against mosquito larvae at an optimum concentration of 70 &mgr;g/ml water (70 ppm) when exposed for 24 hrs.
Still another embodiment of the present invention, wherein the insecticidal activity of the compound against mosquito larvae is selected from culex quinquifasciatus.
Yet another embodiment of the present invention, wherein said compound as acetylcholineesterase inhibitor having potential application as a drug for Alzheimer's disease or dermentia.
The present invention also provides a process for the isolation of 12-(2′-CARBOXY-5′-METHOXYPHENYL)-2,12-DIHYDROXY-DODECA-4-ONE Sporotricolone from the fungus Sporotrichum species, said process comprising the steps of:
(a) extracting the fermented solid with an organic solvent;
(b) filtering the extract of step (a) through a cloth or Whatman filter paper to obtain a clear solution;
(c) evaporating the solution of step (b) under reduced pressure to obtain a crude extract;
(d) purifying the crude extract of step (c) by column chromatography over silica gel and eluting with mixture of organic solvents of increasing polarity;
(e) pooling active eluted fraction of step (d) and further subjected to column chromatography over silica gel by eluting with mixture of organic solvents with increasing polarity;
(f) repooling the active eluted fractions of step (e);
(g) evaporating the pooled fractions of step (f) to get a residue; and
(h) dissolving the residue in step (g) in ethyl acetate to yield the pure compound “Sporotricolone”.
Yet another embodiment of the present invention, a process wherein in step (a) the organic solvent is selected from a group consisting of ethyl acetate, acetone or methanol and preferably ethyl acetate.
Still another embodiment of the present invention, a process wherein in step (d) the mixture of organic solvents is selected from the combination of hexane: diethyl ether and chloroform:methanol mixtures.
Further embodiment of the present invention, a process wherein in step (e) the mixture of organic solvent used is chloroform:ethyl acetate mixture.
Yet another embodiment of the present invention, wherein the said compound is separated and purified by column chromatography on silica gel and RP HPLC.
Still another embodiment of the present invention, wherein said compound having an UV absorption at 265 and 312 nm.
The present invention is further explained in the form of following embodiment

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Compound as cholinesterase inhibitor and its isolation from... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compound as cholinesterase inhibitor and its isolation from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound as cholinesterase inhibitor and its isolation from... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3228818

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.